Fusion Inhibitors (FIs)
Unlike many other classes of antiretrovirals, this newer class of antiretrovirals works by interfering with the activity of HIV before it infects the cell. As their name implies, FIs block viral infection by blocking viral binding sites, which prevents HIV from adhering to the cell surface and subsequently infecting CD4 cells. With no available viral binding site, HIV is unable to introduce viral RNA into the CD4 cell.
FDA-approved FIs
 |
||||||
|
||||||
 |
*The brand listed above is a trademark of its respective owner and is not a trademark of The GlaxoSmithKline Group of Companies. The maker of this brand is not affiliated with and does not endorse GlaxoSmithKline or its products.